Deerfield Beach, FL -- (SBWIRE) -- 01/26/2017 -- Schizophrenia is a severe mental disorder that is characterized by abnormal social behavior and failure to recognize what is real; its symptoms are broadly divided into positive, negative and cognitive. The treatment of schizophrenia is multi-factorial and includes medical, psychological and psychosocial inputs. Antipsychotic medication is the main pharmacological agent used, along with counselling, job training, and social rehabilitation. Both typical and atypical antipsychotics are used, and the choice of medication is usually left to the discretion of the treating physician. Clozapine, which is an atypical antipsychotic that binds to serotonin and dopamine receptors, is often given to patients who do not improve with other antipsychotics.

Current treatments, although effective for positive symptoms, have not proven as effective for negative symptoms and cognitive dysfunction, nor are there are any disease-modifying drugs currently available. The pipeline for schizophrenia is small, particularly given the large patient population, it also has low levels of innovation in comparison to other psychiatric indications in the pharmaceutical industry. However, the overall level of innovation in the pipeline for schizophrenia-related indications (which includes depression, panic disorders, obsessive compulsive disorder, post-traumatic stress disorder and cognitive deficit) is far higher, with these related products having the potential to provide some benefit to patients with schizophrenia.

Browse Complete Report with TOC @ http://www.marketresearchstore.com/report/frontier-pharma-schizophrenia-and-associated-indications-small-57504

Scope

The current clinical landscape of schizophrenia

What is the pathophysiology of schizophrenia?
How is schizophrenia diagnosed?
What are the current treatment options?

The schizophrenia pipeline is small, although there is a much larger pipeline for its related indications.

What are the common targets and mechanisms of action of pipeline therapies?

Will the pipeline address unmet needs such as a lack of diverse treatment options for schizophrenia patients, particularly those with negative or cognitive symptoms?

What is the composition of the pipeline for schizophrenia-related indications, and will they be of benefit to schizophrenia patients?

To Get Sample Copy of Report visit @ http://www.marketresearchstore.com/report/frontier-pharma-schizophrenia-and-associated-indications-small-57504#RequestSample

First-in-class products and targets currently within the schizophrenia pipeline

What are the most promising first-in-class targets for schizophrenia?

Detailed outlook on first-in-class targets and whether they have other therapeutic potential across the industry

Licensing deals are the most common form of strategic alliance in schizophrenia